Eli Lilly and Co on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12. The company said internal testing detected ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly's ...

Eli Lilly & Co. warned that the active ingredient in its weight-loss blockbuster Zepbound could pose a risk to patients when ...

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the ...

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

March 3 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to 30 telehealth companies for making ...

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

Compounded GLP-1s for Weight Loss: What Are They and Are They Safe? GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard ...